Trial Profile

A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adjuvanted imsapepimut and etimupepimut (Primary) ; Pembrolizumab (Primary)
Indications Adenocarcinoma; Bladder cancer; Carcinoma; Head and neck cancer; Non-small cell lung cancer; Oropharyngeal cancer; Pelvic cancer; Renal cancer; Squamous cell cancer; Transitional cell carcinoma; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms Basket trial
Sponsors IO Biotech

08 Apr 2026 Status changed from active, no longer recruiting to completed.
08 Apr 2026 Actual primary completion date changed from 4 Jan 2024 to 30 Nov 2025.
14 Nov 2025 According to an IO Biotech media release, The company presented a poster at ESMO of final data from the Phase 2 basket trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com